

Press release
April 20, 2006
Kungsbacka, Sweden

Proposal concerning members of the Board

Supplement to the notice of the Annual General Meeting to be held on May 4, 2006

Vitrolife's election committee has decided to propose, instead of five members of the Board as previously, that the number of members of the Board of Vitrolife remains unchanged at four in number. Semmy Rölf has previously been proposed for election as a new member of the Board. A presentation follows below. The complete proposal concerning the members of the Board is thereby the re-election of Patrik Tigerschiöld, Per Båtelson and Madeleine Olsson-Eriksson and the new election of Semmy Rölf. The proposal concerning the total Board fees is changed to SEK 300,000 due to the proposal of one less member, with SEK 120,000 to the Chairman of the Board and SEK 60,000 to each of the other members of the Board.

The company has been informed that shareholders representing approximately 35 percent of the shares and votes in the company support the proposal of the election committee.

Semmy Rölf was born in 1950 and is today the Managing Director of Position Skåne, an amalgamation of Skåne's Tourist Board and International Investments within the Business Unit of Region Skåne. He is also on the Board of a number of smaller companies within the medical device area, amongst other things as Chairman of the Board of Jolife AB. Semmy has previously worked, amongst other things, as Managing Director of ProstaLund AB, which works in the field of microwave-based minimally invasive surgery on enlarged prostate glands, and for Axis Communications AB, with business operations within the field of network-based video and print servers. Semmy Rölf holds 40,000 shares in Vitrolife.

April 20, 2006
Kungsbacka, Sweden

The Board

Questions should be addressed to:
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Cell therapy. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Cell therapy product area works with media to enable the use of stem cells for therapeutic purposes.

Vitrolife today has approximately 110 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The Vitrolife share is listed on the O-list of the Stockholm Stock Exchange.

Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.